



## REGISTER OF DECLARED PRIVATE, PROFESSIONAL, COMMERCIAL AND OTHER INTERESTS

Please refer to the attached guidance notes before completing this register entry. In addition to guidance on each section, examples of information required are also provided. Where you have no relevant interests in the relevant category, please enter 'none' in the register entry.

Please return this form by e-mail as a word document.

<b>Name:</b>	Professor Mark H. Wilcox
--------------	--------------------------

**Please list all MRC bodies you are a member of:** E.g. Council, Strategy Board, Research Board, Expert Panel etc and your position (e.g. chair, member).

Infection & Immunity Board member

**Main form of employment:** Name of University and Department or other employing body (include location), and your position.

Professor of Medical Microbiology, Sir Edward Brotherton Chair of Bacteriology (University of Leeds);

Consultant / Head of Microbiology Research & Development (Leeds Teaching Hospitals NHS Trust);

Lead on *C. difficile* infection (Public Health England).

**Research group/department web page:** Provide a link to any relevant web pages for your research group or individual page on your organisation's web site.

[https://medhealth.leeds.ac.uk/profile/300/788/mark\\_wilcox](https://medhealth.leeds.ac.uk/profile/300/788/mark_wilcox)

<http://medhealth.leeds.ac.uk/hcai>

**Please give details of any potential conflicts of interests arising out of the following:**

**1. Personal Remuneration:** Including employment, pensions, consultancies, directorships, honoraria. See section 1 for further guidance.

Prof. Wilcox has received:

- consulting fees from Abbott Laboratories, Actelion, Antabio, AiCuris, Astellas, Astra-Zeneca, Bayer, Biomérieux, Cambimune, Cerexa, Da Volterra, The European Tissue Symposium, Ferring, The Medicines Company, MedImmune, Menarini, Merck, Meridian, Motif Biosciences, Nabriva, Paratek, Pfizer, Qiagen, Roche, Surface Skins, Sanofi-Pasteur, Seres, Summit, Synthetic Biologics and Valneva;
- lecture fees from Abbott, Alere, Allergan, Astellas, Astra-Zeneca, Merck, Pfizer, Roche & Seres;
- grant support from Abbott, Actelion, Astellas, Biomérieux, Cubist, Da Volterra, MicroPharm, Morphochem AG, Sanofi-Pasteur, Seres, Spero, Summit and The European Tissue Symposium, Merck.

**2. Shareholdings and Financial Interests in companies:** Include the names of companies involved in medical/biomedical research, pharmaceuticals, biotechnology, healthcare provision and related fields where shareholdings or other financial interests. See section 2 for thresholds

and further guidance.

None.

**3. Research Income during current session (Financial year):** Declare all research income from bodies supported by the MRC and research income from other sources above the limit of £50k per grant for the year. See section 3 for further guidance.

You do not need to provide the total value of the award or your total anticipated grant income within the year though you may wish to do so.

1. Development and Validation of in vitro Healthy and Dysbiosis Human Microbiota Models to Facilitate Early Phase Antimicrobial Development. Centers for Disease Control (CDC, USA). CDC Broad Agency Announcement FY2017-OADS-01. (2018-19) – £327,740 (\$443,491) (Lead).
2. Leeds NIHR Diagnostic Technologies Medical Technology and In Vitro Diagnostic Co-operative (2017-2022) - £1.3 million (Co-applicant).
3. Combatting Bacterial Resistance in Europe – Clostridium difficile Infections (COMBACTE-CDI). European Union Innovative Medicines Initiative (2017-) – €3 million + €3 million in kind EFPIA contribution (Co-Lead).
4. Development of a rapid, cost effective algorithm to improve detection of intestinal Carbapenemase Producing Enterobacteriaceae. Healthcare Infection Society (2016-) – £139K (Co-applicant).
5. Multisite study to examine the extent of environmental contamination by potential bacterial pathogens, including antibiotic resistant bacteria, in hospital washrooms according to hand drying method. European Tissue Symposium. (2017-) - £120K (Lead).
6. Preclinical development and assessment of an orally administered therapeutic for Clostridium difficile infection. Technology Strategy Board. (2016-) - £160K (Co-investigator).
7. Accelerating development of infection diagnostics for patient management and reduction of antibiotic misuse. MRC. (2016-) - £3.8 million (Co-applicant).
8. Gut model microbiome studies following administration of SER-109. Seres. (2016-) - £120K (Lead).
9. Identification of type *C. difficile* strains with known heritage and properties. BARDA. (2015-16) - £500K (Co-applicant).
10. Evaluation of accuracy of QuikChek Complete compared with toxin and GDH enzyme immunoassays. Alere. (2016-) - £70K (Lead).

**4. Major academic collaborators [national and international]:** Declare all significant collaborations outside your primary institution or organisation. See section 4 for further guidance.

University of Oxford – Professors Crook / Peto and Walker. Modernising Medical Microbiology.

European *C. difficile* infection consortia – EUCLID, LUCID, ORCHID, CDI-COMBACTE.

**5. Un-remunerated involvement with and membership of medical, bio-medical, pharmaceutical, healthcare provision or science organisations or health policy/communication and similar activities/organisations:** This may include non-executive and advisory positions, directorships and other positions of authority. See section 5 for further guidance.

Rapid Review Panel (Public Health England) – Chair.

Antimicrobial Resistance and Healthcare Associated Infection Committee (Dept of Health) – Deputy Chair.

Antimicrobial Resistance and Healthcare Associated Infection Programme Board (Public Health England).

Wellcome Trust/CARB-X Advisory Board – Member.

UK (Public Health England – Lead), European Society of Clinical Microbiology and Infectious Diseases – Member), and US (Infectious Diseases Society of America – Member) working groups on *C. difficile* infection.

**6. Political/pressure group associations:** Members are expected not to occupy paid posts, or hold high-profile unpaid roles within a political party, pressure group or similar organisation. Any political/pressure group association should be declared. See section 6 for further guidance.

None.

**7. Family:** Provide details of any potential conflicts that may arise out of any known interests of immediate family. See section 7 for further guidance.

Please indicate which section (1-6) above applies. Family members do not need to be identified, either by name or their relationship to you.

None.